These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32379447)

  • 1. Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF
    Erdeljac N; Thiehoff C; Jumde RP; Daniliuc CG; Höppner S; Faust A; Hirsch AKH; Gilmour R
    J Med Chem; 2020 Jun; 63(11):6225-6237. PubMed ID: 32379447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
    Maskos K; Bode W
    Mol Biotechnol; 2003 Nov; 25(3):241-66. PubMed ID: 14668538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
    Singh T; Adekoya OA; Jayaram B
    Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities.
    Ndinguri MW; Bhowmick M; Tokmina-Roszyk D; Robichaud TK; Fields GB
    Molecules; 2012 Nov; 17(12):14230-48. PubMed ID: 23201642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
    Fischer T; Senn N; Riedl R
    Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
    Fischer T; Riedl R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
    Bode W; Maskos K
    Biol Chem; 2003 Jun; 384(6):863-72. PubMed ID: 12887053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
    Gimeno A; Cuffaro D; Nuti E; Ojeda-Montes MJ; Beltrán-Debón R; Mulero M; Rossello A; Pujadas G; Garcia-Vallvé S
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated structure- and pharmacophore-based MMP-12 virtual screening.
    Ramezani M; Shamsara J
    Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMP inhibition by barbiturate homodimers.
    Wang J; Radomski MW; Medina C; Gilmer JF
    Bioorg Med Chem Lett; 2013 Jan; 23(2):444-7. PubMed ID: 23246356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
    Jana S; Singh SK
    J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of matrix metalloproteinase function.
    Bode W
    Biochem Soc Symp; 2003; (70):1-14. PubMed ID: 14587278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.
    Sawa M; Kondo H; Nishimura S
    Bioorg Med Chem Lett; 2002 Feb; 12(4):581-4. PubMed ID: 11844676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs.
    Jain M; Harburn JJ; Gill JH; Loadman PM; Falconer RA; Mooney CA; Cobb SL; Berry DJ
    J Med Chem; 2017 May; 60(10):4496-4502. PubMed ID: 28471664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Approaches to Matrix Metalloprotease Drug Design.
    Singh T; Jayaram B; Adekoya OA
    Methods Mol Biol; 2017; 1579():273-285. PubMed ID: 28299743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
    Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
    PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases.
    Aureli L; Gioia M; Cerbara I; Monaco S; Fasciglione GF; Marini S; Ascenzi P; Topai A; Coletta M
    Curr Med Chem; 2008; 15(22):2192-222. PubMed ID: 18781944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling hidden regulatory sites in structurally homologous metalloproteases.
    Udi Y; Fragai M; Grossman M; Mitternacht S; Arad-Yellin R; Calderone V; Melikian M; Toccafondi M; Berezovsky IN; Luchinat C; Sagi I
    J Mol Biol; 2013 Jul; 425(13):2330-46. PubMed ID: 23583775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.